From the Institute of Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Cancer J. 2020 May/Jun;26(3):176-185. doi: 10.1097/PPO.0000000000000451.
Twenty-five years after the Revised European American Classification of Lymphoid Neoplasms classification was published, its principle of an integrative approach to disease definition based on several parameters still prevails and has been adopted and expanded in the following World Health Organization classifications of tumors of the hematopoietic organs. The latest World Health Organization classification revised in 2017 comprises more than 80 entities of mature lymphoid neoplasms (B-cell, T-cell, and Hodgkin lymphomas), which are defined according to their morphology, immunophenotype, genetic lesions and molecular profiles, clinical features, and cellular derivation. The classification also recognizes both incipient and indolent lymphoid neoplasms with a low potential of progression. In this review, we highlight some of the new data and recent modifications introduced in the 2017 classification.
修订后的欧洲-美国淋巴造血组织肿瘤分类发布 25 年后，其基于多个参数的综合疾病定义方法仍然占主导地位，并已被随后的世界卫生组织造血器官肿瘤分类所采用和扩展。最新的 2017 年世界卫生组织分类修订版包括 80 多种成熟淋巴肿瘤（B 细胞、T 细胞和霍奇金淋巴瘤），这些肿瘤根据其形态、免疫表型、遗传病变和分子谱、临床特征和细胞来源进行定义。该分类还认识到具有低进展潜能的初期和惰性淋巴肿瘤。在这篇综述中，我们强调了 2017 年分类中引入的一些新数据和最近的修改。
